Molecular brain imaging in the multimodality era

Journal of Cerebral Blood Flow and Metabolism

Volumn 32, Issue 7, 2012, Pages 1377-1392

  Price, Julie C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's; brain imaging; molecular imaging; MRI; positron emission tomography

Indexed keywords

3 METHYLSPIPERONE F 18; ALTANSERIN F 18; CARFENTANIL C 11; DIPRENORPHINE C 11; FALLYPRIDE F 18; FLUORODEOXYGLUCOSE F 18; GSK 1521498; MU OPIATE RECEPTOR AGONIST; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N ACETYLASPARTIC ACID; NALTREXONE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PE 21; PE 21 C 11; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; WAY 100635 C 11;

ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; BOLD SIGNAL; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN MAPPING; BRAIN METABOLISM; BRAIN REGION; BRAIN SIZE; COMPUTER PROGRAM; DENTATE GYRUS; DIFFUSION TENSOR IMAGING; DISEASE COURSE; EARLY DIAGNOSIS; ENTORHINAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IN VIVO STUDY; INSTRUMENTATION; MEASUREMENT; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NEOCORTEX; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPORAL CORTEX; WHITE MATTER;

ALZHEIMER DISEASE; ANIMALS; BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84863427994     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2012.29     Document Type: Review

References (121)

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:270-9
2. Alzheimer's Association (2010) Alzheimer's disease facts and figures. Alzheimer Dement 6:158-94
3. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK (2005) Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain 9:463-84 (Pubitemid 40836040)
4. Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, Fox NC, Rossor MN (2006) Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 60:145-7
5. Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang GF, Mathis CA, Klunk WE, Hyman BT (2003) Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA 100:12462-7 (Pubitemid 37271582)
6. Bacskai BJ, Klunk WE, Mathis CA, Hyman BT (2002) Imaging amyloid-beta deposits in vivo. J Cereb Blood Flow Metab 22:1035-41
7. Balas C (2009) Review of biomedical optical imaging-a powerful, non-invasive, non-ionizing technology for improving in vivo diagnosis. Meas Sci Technol 20:1-12
8. Blasberg R (2002) Imaging gene expression and endogenous molecular processes: molecular imaging. J Cereb Blood Flow Metab 22:1157-64
9. Boada FE, LaVerde G, Jungreis C, Nemoto E, Tanase C, Hancu I (2005) Loss of cell ion homeostasis and cell viability in the brain: what sodium MRI can tell us. Curr Top Dev Biol 70:77-101 (Pubitemid 43588876)
10. Boas DA, Dale AM, Franceschini MA (2004) Diffuse optical imaging of brain activation: approaches to optimizing image sensitivity, resolution, and accuracy. Neuroimage 23(Suppl 1):S275-88 (Pubitemid 39421725)
11. Buckner RL (2004) Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron 44:195-208 (Pubitemid 39348840)
12. Buckner RL, Andrews-Hanna JR, Schacter DL (2008) The brain's default network: anatomy, function, and relevance to disease. Ann NY Acad Sci 1124:1-38 (Pubitemid 351506788)
13. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA (2005) Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25:7709-17 (Pubitemid 41208641)
14. Buxton RB (2010) Interpreting oxygenation-based neuroimaging signals: the importance and the challenge of understanding brain oxygen metabolism. Front Neuroenergetics 2:8
15. Carhart-Harris RL, Leech R, Williams TM, Erritzoe D, Abbasi N, Bargiotas T, Hobden P, Sharp DJ, Evans J, Feilding A, Wise RG, Nutt DJ (2012) Implications for psychedelic-assisted psychotherapy: a functional magnetic resonance imaging study with psilocybin. Br J Psychiatry 200:238-44
16. Casanova R, Srikanth R, Baer A, Laurienti PJ, Burdette JH, Hayasaka S, Flowers L, Wood F, Maldjian JA (2007) Biological parametric mapping: a statistical toolbox for multimodality brain image analysis. Neuroimage 34:137-43 (Pubitemid 44765265)
17. Catana C, Procissi D,Wu Y, Judenhofer MS, Qi J, Pichler BJ, Jacobs RE, Cherry SR (2008) Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc Natl Acad Sci USA 105:3705-10 (Pubitemid 351723462)
18. Chamberlain R, Wengenack TM, Poduslo JF, Garwood M, Jack Jr CR (2011) Magnetic resonance imaging of amyloid plaques in transgenic mouse models of Alzheimer's disease. Curr Med Imaging Rev 7:3-7
19. Chen YC, Galpern WR, Brownell AL, Matthews RT, Bogdanov M, Isacson O, Keltner JR, Beal MF, Rosen BR, Jenkins BG (1997) Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med 38:389-98 (Pubitemid 27386336)
20. Christensen NL, Hammer BE, Heil BG, Fetterly K (1995) Positron emission tomography within a magnetic field using photomultiplier tubes and lightguides. Phys Med Biol 40:691-7
21. Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, Nebes RD, Saxton JA, Snitz BE, Aizenstein HA, Wolk DA, Dekosky ST, Mathis CA, Klunk WE (2009) Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci 29:14770-8
22. De M, Chou SS, Joshi HM, Dravid VP (2011) Hybrid magnetic nanostructures (MNS) for magnetic resonance imaging applications. Adv Drug Deliv Rev 63:1282-99
23. De Jong HW, van Velden FH, Kloet RW, Buijs FL, Boellaard R, Lammertsma AA (2007) Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol 52:1505-26 (Pubitemid 46646401)
24. Delatour B, Epelbaum S, Petiet A, Dhenain M(2010) In vivo imaging biomarkers in mouse models of Alzheimer's disease: are we lost in translation or breaking through? Int J Alzheimers Dis 2010:pii: 604853
25. De Leon MJ, George AE, Golomb J, Tarshish C, Convit A, Kluger A, De Santi S, McRae T, Ferris SH, Reisberg B, Ince C, Rusinek H, Bobinski M, Quinn B, Miller DC, Wisniewski HM (1997) Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol Aging 18:1-11 (Pubitemid 27062181)
26. De Leon MJ, Mosconi L, Blennow K, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Tsui W, Saint Louis LA, Sobanska L, Brys M, Li Y, Rich K, Rinne J, Rusinek H (2007) Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann NY Acad Sci 1097:114-45 (Pubitemid 47084889)
27. Delso G, Furst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, Schwaiger M, Ziegler SI (2011) Performance measurements of the Siemens mMR integrated wholebody PET/MR scanner. J Nucl Med 52:1914-22
28. Dewey SL, Logan J, Wolf AP, Brodie JD, Angrist B, Fowler JS, Volkow ND (1991) Amphetamine induced decreases in (18F)-N-methylspiroperidol binding in the baboon brain using positron emission tomography (PET). Synapse 7:324-7
29. Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, Bertram L, Mullin K, Tanzi RE, Blacker D, Albert MS, Sperling RA (2005) Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 65: 404-11 (Pubitemid 41099803)
30. Dougherty DD, Kong J, Webb M, Bonab AA, Fischman AJ, Gollub RL (2008) A combined [11C]diprenorphine PET study and fMRI study of acupuncture analgesia. Behav Brain Res 193:63-8
31. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, Minoshima S, Schwaiger M, Kurz A (2005) Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 46:1625-32 (Pubitemid 46211586)
32. Duyn JH, Koretsky AP (2011) Novel frontiers in ultrastructural and molecular MRI of the brain. Curr Opin Neurol 24:386-93
33. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, Hotton G, Cutler D, Fox N, Kennedy A, Rossor M, Brooks DJ (2007) Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 68:501-8
34. Endres CJ, Kolachana BS, Saunders RC, Su T, Weinberger D, Breier A, Eckelman WC, Carson RE (1997) Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies. J Cereb Blood Flow Metab 17:932-42 (Pubitemid 27396581)
35. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Langstrom B, Nordberg A (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129:2856-66 (Pubitemid 44684508)
36. Ewers M, Frisoni GB, Teipel SJ, Grinberg LT, Amaro Jr E, Heinsen H, Thompson PM, Hampel H (2011a) Staging Alzheimer's disease progression with multimodality neuroimaging. Prog Neurobiol 95:535-46
37. Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H (2011b) Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci 34:430-42
38. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59:512-9 (Pubitemid 43358072)
39. Finnema SJ, Varrone A, Hwang TJ, Halldin C, Farde L (2011) Confirmation of fenfluramine effect on 5-HT(1B) receptor binding of [(11)C]AZ10419369 using an equilibrium approach. J Cereb Blood Flow Metab; published online 14 December 2011 (e-pub ahead of print)
40. Friedland RP, Budinger TF, Ganz E, Yano Y,Mathis CA, Koss B, Ober BA, Huesman RH, Derenzo SE (1983) Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr 7:590-8 (Pubitemid 13035941)
41. Frisoni GB, Fox NC, Jack Jr CR, Scheltens P, Thompson PM (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6:67-77
42. Friston KJ, Zarahn E, Josephs O, Henson RN, Dale AM (1999) Stochastic designs in event-related fMRI. Neuroimage 10:607-19
43. Goorden MC, Beekman FJ (2010) High-resolution tomography of positron emitters with clustered pinhole SPECT. Phys Med Biol 55:1265-77
44. Gotz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P, Chen F (2004) Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry 9:664-83 (Pubitemid 38932172)
45. Greicius MD, Krasnow B, Reiss AL, Menon V (2003) Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci USA 100:253-8 (Pubitemid 36078061)
46. Greicius MD, Srivastava G, Reiss AL, Menon V (2004) Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 101:4637-42 (Pubitemid 38437463)
47. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-6 (Pubitemid 34790756)
48. Hayasaka S, Du AT, Duarte A, Kornak J, Jahng GH, Weiner MW, Schuff N (2006) A non-parametric approach for co-analysis of multi-modal brain imaging data: application to Alzheimer's disease. Neuroimage 30:768-79
49. Heiss WD, Raab P, Lanfermann H (2011) Multimodality assessment of brain tumors and tumor recurrence. J Nucl Med 52:1585-600
50. Herholz K, Carter SF, Jones M (2007) Positron emission tomography imaging in dementia. Br J Radiol 80(Spec No 2):S160-7 (Pubitemid 351799343)
51. Herzog H, Langen KJ, Weirich C, Rota Kops E, Kaffanke J, Tellmann L, Scheins J, Neuner I, Stoffels G, Fischer K, Caldeira L, Coenen HH, Shah NJ (2011) High resolution BrainPET combined with simultaneous MRI. Nuklearmedizin 50:74-82
52. Huettel S, Song A, McCarthy G (2009) Functional Magnetic Resonance Imaging. 2nd ed. Sunderland, MA: Sinauer Associates
53. Huppert TJ, Diamond SG, Boas DA (2008) Direct estimation of evoked hemoglobin changes by multimodality fusion imaging. J Biomed Opt 13:054031
54. Iida H, Sasaki H, Inoue H, Kanno I, Miura S, Okuyama D, Uemura K (1986) [A simulation study to evaluate the statistical noise and spatial resolution in image reconstruction of emission computed tomography-with respect to the optimization of the filter function in the convolution integral]. Radioisotopes 35:589-94
55. Jack Jr CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:257-62
56. Jack Jr CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132: 1355-65
57. Jack Jr CR, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Tangalos EG, Kokmen E (2000) Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55:484-9 (Pubitemid 30647242)
58. Jack Jr CR, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E (1999) Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52:1397-403 (Pubitemid 29190530)
59. Jacobs A, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L, Kaestle C, Wagner R, Wienhard K, Heiss WD (2001) Positron-emission tomography of vectormediated gene expression in gene therapy for gliomas. Lancet 358:727-9 (Pubitemid 32823405)
60. Jagust WJ, Eberling JL, Reed BR, Mathis CA, Budinger TF (1997) Clinical studies of cerebral blood flow in Alzheimer's disease. Ann NY Acad Sci 826:254-62 (Pubitemid 27478047)
61. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-19 (Pubitemid 38269583)
62. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA (2005) Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25:10598-606 (Pubitemid 41681907)
63. Krishnan A, Williams LJ, McIntosh AR, Abdi H (2011) Partial least squares (PLS) methods for neuroimaging: a tutorial and review. Neuroimage 56:455-75
64. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-51 (Pubitemid 30164887)
65. Lassen N, Perl W (1979) Tracer Kinetic Methods in Medical Physiology. New York: Raven Press
66. Leroy C, Comtat C, Trebossen R, Syrota A, Martinot JL, Ribeiro MJ (2007) Assessment of 11C-PE2I binding to the neuronal dopamine transporter in humans with the high-spatial-resolution PET scanner HRRT. J Nucl Med 48:538-46 (Pubitemid 47571407)
67. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC (2005) Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46:1959-72 (Pubitemid 46657441)
68. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, Staufenbiel M, Iwata N, Ono M, Saido TC, Suzuki K, Mori H, Higuchi M, Suhara T (2007) Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 27:10957-68
69. Mankoff DA (2007) A definition of molecular imaging. J Nucl Med 48:18N, 21N
70. Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17:545-80 (Pubitemid 36307540)
71. Mathis CA, Lopresti BJ, Klunk WE (2007) Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol 34:809-22 (Pubitemid 47503823)
72. Matthews PM, Honey GD, Bullmore ET (2006) Applications of fMRI in translational medicine and clinical practice. Nat Rev Neurosci 7:732-44 (Pubitemid 44267497)
73. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:263-9
74. Mevel K, Chetelat G, Eustache F, Desgranges B (2011) The default mode network in healthy aging and Alzheimer's disease. Int J Alzheimers Dis 2011:535816
75. Minoshima S, Foster NL, Kuhl DE (1994) Posterior cingulate cortex in Alzheimer's disease. Lancet 344:895 (Pubitemid 24290409)
76. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67:446-52 (Pubitemid 44214969)
77. Mitsis GD, Iannetti GD, Smart TS, Tracey I, Wise RG (2008) Regions of interest analysis in pharmacological fMRI: how do the definition criteria influence the inferred result? Neuroimage 40:121-32
78. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67:122-31
79. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ (2008) Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 49:390-8 (Pubitemid 351355204)
80. Newberg AB, Wang J, Rao H, Swanson RL, Wintering N, Karp JS, Alavi A, Greenberg JH, Detre JA (2005) Concurrent CBF and CMRGlc changes during human brain activation by combined fMRI-PET scanning. Neuroimage 28:500-6 (Pubitemid 41443519)
81. Paneda A, Collantes M, Beattie SG, Otano I, Snapper J, Timmermans E, Guembe L, Petry H, Lanciego JL, Benito A, Prieto J, Rodriguez-Pena MS, Penuelas I, Gonzalez-Aseguinolaza G (2011) Adeno-associated virus liver transduction efficiency measured by in vivo [18F]FHBG positron emission tomography imaging in rodents and nonhuman primates. Hum Gene Ther 22:999-1009
82. Pastor P, Goate AM (2004) Molecular genetics of Alzheimer's disease. Curr Psychiatry Rep 6:125-33 (Pubitemid 38899262)
83. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG (1997) Aging, memory, and mild cognitive impairment. Int Psychogeriatr 9 (Suppl 1):65-9 (Pubitemid 28045341)
84. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25:1528-47 (Pubitemid 41541962)
85. Rabiner EA, Beaver J, Makwana A, Searle G, Long C, Nathan PJ, Newbould RD, Howard J, Miller SR, Bush MA, Hill S, Reiley R, Passchier J, Gunn RN, Matthews PM, Bullmore ET (2011) Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food rewardrelated brain activation in humans. Mol Psychiatry 16:826-35, 785
86. Raichle ME, Snyder AZ (2007) A default mode of brain function: a brief history of an evolving idea. Neuroimage 37:1083-90; discussion 97-99 (Pubitemid 47385262)
87. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J (2001) Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 98:3334-9 (Pubitemid 32220846)
88. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D (1996) Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.[see comment]. N Engl J Med 334:752-8 (Pubitemid 26089356)
89. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 106:6820-5
90. Ridler K, Plisson C, Rabiner EA, Gunn RN, Easwaramoorthy B, Abi-Dargham A, Laruelle M, Slifstein M (2011) Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [11C] P943: a positron emission tomography study in Papio anubis. Synapse 65:1119-27
91. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M (2010) 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363-72
92. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31:1275-83
93. Schlemmer HP, Pichler BJ, Schmand M, Burbar Z, Michel C, Ladebeck R, Jattke K, Townsend D, Nahmias C, Jacob PK, Heiss WD, Claussen CD (2008) Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology 248:1028-35
94. Slifstein M, Kegeles LS, Xu X, Thompson JL, Urban N, Castrillon J, Hackett E, Bae SA, Laruelle M, Abi-Dargham A (2010) Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride. Synapse 64:350-62
95. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack Jr CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:280-92
96. Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, Buckner RL, Becker JA, Johnson KA (2009) Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63:178-88
97. Spires TL, Hyman BT (2005) Transgenic models of Alzheimer's disease: learning from animals. NeuroRx 2:423-37 (Pubitemid 41444876)
98. Stout DB, Zaidi H (2009) Preclinical multimodality imaging in vivo. PET Clin 3:251-73
99. Tartaglia MC, Rosen HJ, Miller BL (2011) Neuroimaging in dementia. Neurotherapeutics 8:82-92
100. Thomason ME, Thompson PM (2011) Diffusion imaging, white matter, and psychopathology. Annu Rev Clin Psychol 7:63-85
101. Thompson PM, Hayashi KM, De Zubicaray GI, Janke AL, Rose SE, Semple J, Hong MS, Herman DH, Gravano D, Doddrell DM, Toga AW (2004) Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage 22:1754-66 (Pubitemid 38962663)
102. Tong Y, Lindsey KP, de BFB (2011) Partitioning of physiological noise signals in the brain with concurrent near-infrared spectroscopy and fMRI. J Cereb Blood Flow Metab 31:2352-62
103. Townsend DW (2008) Multimodality imaging of structure and function. Phys Med Biol 53:R1-39
104. Toyama H, Ye D, Ichise M, Liow JS, Cai L, Jacobowitz D, Musachio JL, Hong J, Crescenzo M, Tipre D, Lu JQ, Zoghbi S, Vines DC, Seidel J, Katada K, Green MV, Pike VW, Cohen RM, Innis RB (2005) PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging 32:593-600 (Pubitemid 41214203)
105. Viale A, Reineri F, Santelia D, Cerutti E, Ellena S, Gobetto R, Aime S (2009) Hyperpolarized agents for advanced MRI investigations. Q J Nucl Med Mol Imaging 53: 604-617
106. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC (2011) Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69:181-92
107. Waerzeggers Y, Monfared P, Viel T, Winkeler A, Jacobs AH (2010) Mouse models in neurological disorders: applications of non-invasive imaging. Biochim Biophys Acta 1802:819-39
108. Wang DJ, Chen Y, Fernandez-Seara MA, Detre JA (2011) Potentials and challenges for arterial spin labeling in pharmacological magnetic resonance imaging. J Pharmacol Exp Ther 337:359-66
109. Wang L, Zang Y, He Y, Liang M, Zhang X, Tian L, Wu T, Jiang T, Li K (2006) Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. Neuroimage 31:496-504 (Pubitemid 43776683)
110. Wehrl HF, Judenhofer MS, Wiehr S, Pichler BJ (2009) Preclinical PET/MR: technological advances and new perspectives in biomedical research. Eur J Nucl Med Mol Imaging 36(Suppl 1):S56-68
111. Weiner MW, Aisen PS, Jack Jr CR, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M (2010) The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 6:202-11e7
112. Wise RG, Rogers R, Painter D, Bantick S, Ploghaus A, Williams P, Rapeport G, Tracey I (2002) Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanil. Neuroimage 16:999-1014
113. Wolf RL, Detre JA (2007) Clinical neuroimaging using arterial spin-labeled perfusion magnetic resonance imaging. Neurotherapeutics 4:346-59 (Pubitemid 46962404)
114. Wolk DA, Klunk W (2009) Update on amyloid imaging: from healthy aging to Alzheimer's disease. Curr Neurol Neurosci Rep 9:345-52
115. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD,Weissfeld LA, Mathis CA, Klunk WE, DeKosky ST (2009) Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65:557-68
116. Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, Czernin J, Gambhir SS (2009) Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat Clin Pract Oncol 6:53-8
117. Ye JC, Tak S, Jang KE, Jung J, Jang J (2009) NIRS-SPM: statistical parametric mapping for near-infrared spectroscopy. Neuroimage 44:428-47
118. Yip CY, Fessler JA, Noll DC (2006) Advanced threedimensional tailored RF pulse for signal recovery in T2*-weighted functional magnetic resonance imaging. Magn Reson Med 56:1050-9 (Pubitemid 44691347)
119. Zaharchuk G, Bogdanov Jr AA, Marota JJ, Shimizu-Sasamata M, Weisskoff RM, Kwong KK, Jenkins BG, Weissleder R, Rosen BR (1998) Continuous assessment of perfusion by tagging including volume and water extraction (CAPTIVE): a steady-state contrast agent technique for measuring blood flow, relative blood volume fraction, and the water extraction fraction. Magn Reson Med 40: 666-78 (Pubitemid 28493642)
120. Zhu H, Barker PB (2011) MR spectroscopy and spectroscopic imaging of the brain. Methods Mol Biol 711:203-26
121. Zimmer L, Luxen A (2011) PET radiotracers for molecular imaging in the brain: Past, present and future. Neuroimage; published online 28 December 2011 [e-pub ahead of print]